News

Labiotech.eu1d

Injecting hope into skin cancer treatment: The promise of melanoma vaccines

Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly ...

REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...

5 Insightful Analyst Questions From Regeneron’s Q2 Earnings Call

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...
Stocktwits on MSN3d

This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...